Introduction
Corticosteroids (CS) induce apoptosis and cell cycle arrest in the majority of malignant lymphoid cells(1). Consequently they are critical component of combination chemotherapy regimens used in the treatment of lymphoid malignancies, including childhood acute lymphoblastic leukemia (ALL) (2) ; (3) . Despite their clinical importance, the mechanism underlying molecular basis of CS-induced apoptosis and CS-related resistance are not fully understood. CSs mediate their effect via glucocorticoid receptor (GR) (4) ; (5) ; the resulting complex recruits either co-activator or co-repressor proteins thereby inducing or repressing the expression of a large number of target genes (4, (6) (7) (8) . A subpopulation of childhood ALL cases fail to respond to CS treatment and one of the underlying mechanisms is a change in GR expression (5) ; (9) ; (10) . Other mechanisms are also involved in the resistance to cell death induced by these drugs. A number of studies including genome-wide expression profiling have attempted to identify critical glucocorticoid-regulated genes, which may undergo altered expression before the onset of apoptosis (11) (12) (13) (14) . The proapoptotic protein that was up-regulated by glucocorticoids in several models of CS-induced apoptosis is Bim, the Bcl-2 homology 3 (BH3)-only molecule (11) ; (15) ; (16). Bim is expressed in hematopoietic, epithelial, neuronal, and germ cells and was found frequently up-regulated in childhood leukemia samples following CS exposure. (11) ; (13) It is a member of Bcl-2 family that induces the mitochondrial apoptosis pathway by either opposing the pro-survival proteins of this family or by binding to the pro-apoptotic Bcl2 members directly activating their proapoptotic functions (17) 6 CS in ALL and, as shown in primary ALL lymphoblasts, cell lines and ALL xenografts, resistance to CS is associated with attenuated induction of Bim (15, 19-21).
Bim is encoded by gene BCL2L11 and three major mRNA isoforms and Bim protein products (BimEL, BimS, and BimL) exist(15). Moreover, it is extensively regulated at transcriptional and post-transcriptional level. The changes in expression may be also affected by genetic polymorphisms.
Here we report the analysis of Bim polymorphisms and their association with ALL disease outcomes in two patient populations. Further functional analysis based on mRNA and cellular viability assays was also performed to give an insight into the underlying mechanism of significant association.
Patients and methods

Study population and endpoints in the analysis
The study population consisted of 348 Caucasian children (97.5% of patients are of The characteristics of patients for both test and validations set are provided in Table 1 .
Genotyping
Thirty two polymorphisms located in regulatory and coding gene regions were selected Eight tagSNPs (sufficient to define common haplotypes) with minor allele frequency (MAF) ≥ 5% were retained for analysis in patients. Primers and probes used for amplification and genotyping of these polymorphisms are shown in supplemental Table   1 . dbSNP numbers along with SNP positions for the polymorphisms genotyped only in controls are given in supplemental Table 2 . The subset of samples was genotyped in duplicate to ensure genotype reproducibility. Genotyping was performed by allele specific oligonucleotide hybridization as previously described(26).
Statistics
The estimates of linkage disequilibrium (LD), and haplotype phase in control individuals were obtained by PHASE software, version 2.0(27). The tag SNPs were selected based on LD information (r 2 , Figure 1 ) using Haploview software. Association of genotypes with ALL outcome was assessed by EFS and OS. Survival differences, estimated by Kaplan-Meier analysis for patients with different genotypes, were assessed using a logrank test. Times to event, or a death were measured as the time between diagnosis and the event of interest. For censored cases, it represented the time from diagnosis to date last known alive without an event; for longer follow-up durations all times were truncated at 5 years post-treatment. For the polymorphism associated with a disease outcome, the analyses were also performed following stratification by risk group and CS type. The hazard ratio (HR, with a 95% confidence interval, CI) for genetic variants was estimated by Cox regression analysis. Cox regression was also used to estimate multivariable HR in the presence of common prognostic factors (age, sex, presenting white blood cell (WBC) Semi-quantitative analysis of three major RNA isoform (Bim S, Bim L and Bim EL, Figure 2 ) was carried out by using primers described in(31), whereas γ1 and γ2 assessment was carried out by same PCR primers described above for total γ estimation.
Research. (1200) (fragment size range of 15 bp-3 kb) was chosen to recognize size differences of amplicons; Electropherogram and gel images were generated for each lane; Biocalculator software was used for data export and analysis. Relative contribution of each isoform (expressed as ratio of normalized areas under the curve) was analysed as quartile distribution in relation to genotype using chi-square test.
The sequence of the two gamma isoforms (gamma 1 and 2) were confirmed by Sanger sequencing. Genotyping of LCLs was performed as described above.
Cellular proliferation assay
LCLs were cultured in RPMI medium supplemented with 15% fetal bovine serum and antibiotics (100 IU/ml penicillin; 100 μg/ml streptomycin). The experiments were carried out to determine the concentrations lethal to 50% of the cells (IC50) during cell survival was calculated as (OD drug-exposed well)/(mean OD control wells)×100%.
Log-transformed values or quartile distribution was compared in relation to genotypes.
Results
Thirty two polymorphisms located in the region of potential functional importance (regulatory and coding regions) were genotyped in 60 controls of Caucasian origin to estimate allelic frequency ( Figure 1A) ; Polymorphisms with MAF ≥5% were analyzed for pairwise LD ( Figure 1B) ; eight tagSNPs were identified (sufficient to define six common haplotypes, arbitrarily named *1 to *6, Figure 1C ) and retained for the analysis in patients.
The analysis in the discovery cohort revealed no association with EFS (Table 2 ). In contrast, the analysis showed significant association between OS and synonymous C29201T replacement (Ile65Ile) located in BH3 domain of exon 8 (p=0.01, HR=1.9, 95% CI, 1.1-3.1, Figure 3A and Table 2 ) with lowest OS seen in patients with TT29201
genotype. The association remained significant (HR=2.1, 95% CI, 1.2-3.7, p=0.007) with inclusion of typical prognostic factor in Cox regression model (see methods). Given that patients were administered either prednisone or dexamethasone during the intensification and continuation treatment phases and that doses differed between standard risk (SR) and high risk (HR) patients, C29201T was subsequently analyzed following stratification by CS type and risk groups. Lower OS for TT29201 individuals was noted in patients who received dexamethasone (p=0.009, HR=6.3, 95% CI, 1.3-31.4. Figure 3B ) as well in patients who were assigned to HR group irrespective of type of CS received (p=0.004, HR=3.6, 95% CI, 1.3-10.4, Figure 3B ). The T29201 allele defines haplotype *1, and the same result as for the T allele, was obtained when this haplotype was analyzed for an association with OS (not shown). The analysis for C29201T variation was subsequently performed in the replication cohort (DFCI group of patients). The significant association between genotype groups and OS was seen (p=0.03, HR= 1.9, 95% CI, 1.1-3.4, Figure   3C ), and remained significant in multivariable analysis (HR= 2.4, 95% CI, 1.2-4.7, p=0.01). Reduction in OS was observed for both CT and TT individuals; the TT29201 individuals had nevertheless the lowest EFS among patients who received dexamethasone (p=0.04, Figure 2C ).
The C29201T polymorphism seems to affect exonic splicer element in BH3 domain, as based on F-SNP prediction tool(32), introducing additional binding site to serine and arginin rich (SR) protein SRp55. We therefore performed quantitative and semiquantitative mRNA analysis in lymphoblastoid cell lines (LCL) following addition of prednisone or dexamethasone to investigate whether it may affect the total Bim mRNA levels (except gamma), levels of major (BimS, BimL and BimEL) isoforms, or levels of gamma isoforms (total and γ1/ γ2 ratio), which lack BH3 domain and correlate with reduced apoptotic function. (29, 33) Bim gene organization with respective mRNA isoforms is schematically presented in Figure 2 . The influence of genotypes on sensitivity to CS was tested by in vitro cellular viability assay following addition of either prednisone or dexamethasone to LCLs. There was no relation between C29201T genotypes and mRNA levels when either total or major individual isoforms were quantified. In contrast, non-significant increase in gamma isoform formation was noted in LCLs carrying T29201 allele after addition of dexamethasone, which seems to be due to an increase in gamma1 to gamma2 ratio (Figure 4 , p=0.03). There was no significant change in cellular viability in relation to C29201T genotype. A. A C C T C -G C G G G C G T T G C C G G C - C(Ile) G T A A A G 
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